NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ — Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) .
“We are pleased to have initiated this important Phase 2 trial, which brings us closer to delivering a new treatment option for patients with atopic dermatitis,” said Hugh M. Davis, Ph.D. Chief Business and Development Officer & President, Biosion USA. “This marks another important clinical milestone for Biosion in our effort to develop more high value treatment options for patients.”
The phase I study of BSI-045B demonstrated its potential to be a first-in-class treatment for AD due to its single dose activity in a cohort of AD patients, excellent PK and favorable safety profile. The phase II study is designed to assess the efficacy of BSI-045B as monotherapy as well as in combination therapy with Dupixent® to further increase therapeutic effectiveness for patients who are suffering from AD.
For additional information on this trial (NCT05114889), please visit www.clinicaltrials.gov
About BSI-045B
BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases. Biosion’s collaboration partner – CTTQ, a China-based pharmaceutical company with rights to BSI-045B (TQC2731) for China development and commercialization, is currently conducting a Phase II clinical trial of BSI-045B in China for the treatment of severe uncontrolled asthma.
About Biosion
Biosion is a global, clinical-stage biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017, Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H³ antibody discovery platform, SynTracer® high-throughput endocytosis platform, and Flexibody® bispecific platform. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in phase-II for severe asthma and phase-I for atopic dermatitis. Biosion and partners have plans to progress the immune-oncology and antibody drug conjugate-based portfolio into clinical trials for oncology indications over the next year. Biosion has operations in the US, Australia, and China.To learn more about Biosion, please go to www.biosion.com.
View original content:https://www.prnewswire.com/news-releases/biosion-announces-phase-ii-study-start-for-anti-tslp-mab-bsi-045b-in-atopic-dermatitis-adamant-301889071.html
SOURCE Biosion, Inc.
Featured image: Megapixl © Alex011973